Drug screening platform using human induced pluripotent stem cell-derived atrial cardiomyocytes and optical mapping
© 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press..
Current drug development efforts for the treatment of atrial fibrillation are hampered by the fact that many preclinical models have been unsuccessful in reproducing human cardiac physiology and its response to medications. In this study, we demonstrated an approach using human induced pluripotent stem cell-derived atrial and ventricular cardiomyocytes (hiPSC-aCMs and hiPSC-vCMs, respectively) coupled with a sophisticated optical mapping system for drug screening of atrial-selective compounds in vitro. We optimized differentiation of hiPSC-aCMs by modulating the WNT and retinoid signaling pathways. Characterization of the transcriptome and proteome revealed that retinoic acid pushes the differentiation process into the atrial lineage and generated hiPSC-aCMs. Functional characterization using optical mapping showed that hiPSC-aCMs have shorter action potential durations and faster Ca2+ handling dynamics compared with hiPSC-vCMs. Furthermore, pharmacological investigation of hiPSC-aCMs captured atrial-selective effects by displaying greater sensitivity to atrial-selective compounds 4-aminopyridine, AVE0118, UCL1684, and vernakalant when compared with hiPSC-vCMs. These results established that a model system incorporating hiPSC-aCMs combined with optical mapping is well-suited for preclinical drug screening of novel and targeted atrial selective compounds.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Stem cells translational medicine - 10(2021), 1 vom: 02. Jan., Seite 68-82 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gunawan, Marvin G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atrial differentiation |
|---|
| Anmerkungen: |
Date Completed 21.03.2022 Date Revised 21.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/sctm.19-0440 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31499517X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31499517X | ||
| 003 | DE-627 | ||
| 005 | 20231225153938.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/sctm.19-0440 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1049.xml |
| 035 | |a (DE-627)NLM31499517X | ||
| 035 | |a (NLM)32927497 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gunawan, Marvin G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug screening platform using human induced pluripotent stem cell-derived atrial cardiomyocytes and optical mapping |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2022 | ||
| 500 | |a Date Revised 21.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press. | ||
| 520 | |a Current drug development efforts for the treatment of atrial fibrillation are hampered by the fact that many preclinical models have been unsuccessful in reproducing human cardiac physiology and its response to medications. In this study, we demonstrated an approach using human induced pluripotent stem cell-derived atrial and ventricular cardiomyocytes (hiPSC-aCMs and hiPSC-vCMs, respectively) coupled with a sophisticated optical mapping system for drug screening of atrial-selective compounds in vitro. We optimized differentiation of hiPSC-aCMs by modulating the WNT and retinoid signaling pathways. Characterization of the transcriptome and proteome revealed that retinoic acid pushes the differentiation process into the atrial lineage and generated hiPSC-aCMs. Functional characterization using optical mapping showed that hiPSC-aCMs have shorter action potential durations and faster Ca2+ handling dynamics compared with hiPSC-vCMs. Furthermore, pharmacological investigation of hiPSC-aCMs captured atrial-selective effects by displaying greater sensitivity to atrial-selective compounds 4-aminopyridine, AVE0118, UCL1684, and vernakalant when compared with hiPSC-vCMs. These results established that a model system incorporating hiPSC-aCMs combined with optical mapping is well-suited for preclinical drug screening of novel and targeted atrial selective compounds | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a atrial differentiation | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a cardiomyocyte subtype | |
| 650 | 4 | |a drug screening | |
| 650 | 4 | |a human induced pluripotent stem cells | |
| 700 | 1 | |a Sangha, Sarabjit S |e verfasserin |4 aut | |
| 700 | 1 | |a Shafaattalab, Sanam |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Heims-Waldron, Danielle A |e verfasserin |4 aut | |
| 700 | 1 | |a Bezzerides, Vassilios J |e verfasserin |4 aut | |
| 700 | 1 | |a Laksman, Zachary |e verfasserin |4 aut | |
| 700 | 1 | |a Tibbits, Glen F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stem cells translational medicine |d 2012 |g 10(2021), 1 vom: 02. Jan., Seite 68-82 |w (DE-627)NLM217286267 |x 2157-6580 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:1 |g day:02 |g month:01 |g pages:68-82 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/sctm.19-0440 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 1 |b 02 |c 01 |h 68-82 | ||